adriamycinol has been researched along with Cardiotoxicity in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Challa, VS; Gangasani, JK; Jain, S; Kundu, GC; Naidu, VGM; Panda, SR; Rajdev, B; Syamprasad, NP; Vaidya, JR | 1 |
| Hao, G; Hao, K; Luo, D; Niu, F; Sun, Y; Wang, G; Wu, L; Wu, X; Ye, W; Zhang, J; Zheng, Y; Zhou, F | 1 |
2 other study(ies) available for adriamycinol and Cardiotoxicity
| Article | Year |
|---|---|
AKR1B1 inhibition using NARI-29-an Epalrestat analogue-alleviates Doxorubicin-induced cardiotoxicity via modulating Calcium/CaMKII/MuRF-1 axis.
Topics: Aldehyde Reductase; Animals; Apoptosis; Calcium; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Cardiotoxicity; Doxorubicin; Mice; Myocytes, Cardiac; Oxidative Stress; Rhodanine | 2023 |
Protective effect of 23-hydroxybetulinic acid on doxorubicin-induced cardiotoxicity: a correlation with the inhibition of carbonyl reductase-mediated metabolism.
Topics: Alcohol Oxidoreductases; Animals; Apoptosis; Cardiotoxicity; Cell Proliferation; Cell Survival; Cells, Cultured; Cytoprotection; Dose-Response Relationship, Drug; Doxorubicin; Enzyme Inhibitors; Male; Mice; Mice, Inbred BALB C; Molecular Docking Simulation; Rats; Structure-Activity Relationship; Triterpenes | 2015 |